Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1671
This examiner grants 54% of resolved cases
Cheng Lu works in Art Unit 1642 within Tech Center 1600. The examiner has 218 resolved cases and an allowance rate of 54.1 percent. This provides a baseline for success in this technology area, indicating that just over half of the applications reach a grant. Practitioners can use the 54.1 percent figure to manage client expectations regarding the likelihood of a favorable outcome.
The interview lift is 64.1 percent. This is an extremely high figure, suggesting that interviews are the most effective way to secure an allowance with this examiner. Practitioners should almost certainly schedule an interview to take advantage of this 64.1 percent lift, as it represents a massive increase in the probability of success compared to written responses alone. Verbal engagement appears to be the primary driver of allowances.
The median days to allowance is 1197. This duration indicates that the prosecution process typically takes over three years. However, the high interview lift of 64.1 percent may help in navigating the 1197-day median more effectively by resolving issues earlier in the process. These metrics together suggest that while the timeline is long, a proactive interview strategy can significantly improve results.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17630075 | ANTIBODY PRE-LOADED CD16+NK-92 CELLS AS AN EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS | Non-Final OA | ImmunityBio, Inc. |
| 18480778 | COMPOSITIONS AND METHODS FOR TARGETING AND KILLING ALPHA-V BETA-3-POSITIVE CANCER STEM CELLS (CSCS) AND TREATING DRUG RESISTANT CANCERS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17928767 | INHIBITION OF BMI1 ELIMINATES CANCER STEM CELLS AND ACTIVATES ANTITUMOR IMMUNITY | Non-Final OA | The Regents of the University of California |
| 17598690 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | Non-Final OA | The Johns Hopkins University |
| 18246052 | NOVEL HUMAN ANTIBODIES BINDING TO HUMAN CD3 EPSILON | Non-Final OA | MORPHOSYS GMBH |
| 17796179 | METHODS FOR DIAGNOSING AND TREATING UVEAL MELANOMA | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18270160 | MULTISPECIFIC ANTIGEN BINDING PROTEINS | Non-Final OA | WUXI BIOLOGICS IRELAND LIMITED |
| 18670314 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 17297771 | METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | Final Rejection | Juno Therapeutics, Inc. |
| 17603821 | CHIMERIC RECEPTOR THAT RECOGNIZES ENGINEERED SITE IN ANTIBODY | Non-Final OA | Yamaguchi University |
| 18573641 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Non-Final OA | TORAY INDUSTRIES, INC. |
| 18256777 | FORMULATION FOR MULTI-PURPOSE APPLICATION | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 16317943 | TREATMENT AND PREVENTION OF CYTOKINE RELEASE SYNDROME USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH A KINASE INHIBITOR | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17829164 | ANTI-CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE | Non-Final OA | The Government of the United States, as represented by the Secretary of the Army |
| 18427042 | METHOD OF USING PACAP AND VIP PEPTIDES FOR DETECTING SHED OR CIRCULATING TUMOR CELLS IN BIOLOGICAL FLUIDS | Non-Final OA | Thomas Jefferson University |
| 17626185 | HETERODIMERS AND METHODS OF USE THEREOF | Non-Final OA | Thomas Jefferson University |
| 17775203 | ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY | Final Rejection | Baylor College of Medicine |
| 17626941 | METHODS AND COMPOSITIONS FOR TARGETING TGF-ß SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY | Non-Final OA | Memorial Sloan Kettering Cancer Center |
| 18010647 | ANTIBODIES TO INTERLEUKIN-1BETA AND USES THEREOF | Non-Final OA | ACADEMIA SINICA |
| 18281849 | ANTIBODY FUSION PROTEINS AND USES THEREOF | Non-Final OA | Nanjing GenScript Biotech Co., Ltd. |
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | Non-Final OA | Seagen Inc. |
| 18037219 | METHODS FOR TREATING INFLAMMATORY SKIN CONDITIONS | Final Rejection | CSL INNOVATION PTY LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy